Get the Stockscreener App
25.48
0.08%
-0.02
Pacira Biosciences Inc stock is traded at $25.48, with a volume of 365.21K.
It is down -0.08% in the last 24 hours and up +8.80% over the past month.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
See More
Previous Close:
$25.50
Open:
$25.55
24h Volume:
365.21K
Relative Volume:
0.73
Market Cap:
$1.00B
Revenue:
$734.86M
Net Income/Loss:
$5.14M
P/E Ratio:
203.84
EPS:
0.125
Net Cash Flow:
$132.71M
1W Performance:
+0.35%
1M Performance:
+8.80%
6M Performance:
+8.29%
1Y Performance:
+7.56%
1-Day Range:
$24.90
$25.55
1-Week Range:
$24.86
$26.66
52-Week Range:
$18.80
$27.64
Pacira Biosciences Inc Stock (PCRX) Company Profile
Name
Pacira Biosciences Inc
Sector
Phone
650-242-8052
Address
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
Compare PCRX vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
25.48 | 1.00B | 734.86M | 5.14M | 132.71M | 0.125 |
TAK
Takeda Pharmaceutical Co Adr
|
16.56 | 52.88B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.76 | 42.98B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.95 | 38.37B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
75.56 | 31.68B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
547.06 | 23.22B | 3.17B | 1.29B | 1.01B | 27.09 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Equal Weight |
| Nov-17-25 | Initiated | H.C. Wainwright | Buy |
| Jul-25-25 | Upgrade | Truist | Hold → Buy |
| Jan-30-25 | Upgrade | Truist | Sell → Hold |
| Aug-13-24 | Downgrade | Truist | Buy → Sell |
| Aug-12-24 | Downgrade | JP Morgan | Overweight → Underweight |
| Aug-12-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-12-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-12-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-03-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-07-24 | Resumed | JP Morgan | Overweight |
| Dec-20-23 | Initiated | Raymond James | Outperform |
| Aug-03-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Jan-31-23 | Resumed | Wedbush | Outperform |
| Oct-21-22 | Resumed | Jefferies | Buy |
| Jan-03-22 | Resumed | JP Morgan | Overweight |
| Jul-26-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-21-21 | Resumed | JP Morgan | Neutral |
| Apr-09-21 | Initiated | Berenberg | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-11-21 | Downgrade | Northland Capital | Outperform → Market Perform |
| Jan-21-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-21-20 | Upgrade | Northland Capital | Market Perform → Outperform |
| Jul-06-20 | Reiterated | Needham | Buy |
| May-27-20 | Initiated | Guggenheim | Neutral |
| Apr-07-20 | Initiated | Northland Capital | Outperform |
| Mar-20-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Feb-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-24-20 | Initiated | SunTrust | Buy |
| Jan-23-20 | Initiated | SunTrust | Buy |
| Nov-06-19 | Initiated | BTIG Research | Buy |
| Jun-11-19 | Initiated | Barclays | Overweight |
| May-06-19 | Upgrade | Mizuho | Underperform → Neutral |
| May-02-19 | Upgrade | Stifel | Sell → Hold |
| Feb-01-19 | Downgrade | Mizuho | Neutral → Underperform |
| Aug-06-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Apr-09-18 | Reiterated | H.C. Wainwright | Buy |
| Mar-21-18 | Reiterated | Mizuho | Neutral |
| Feb-16-18 | Downgrade | Needham | Buy → Hold |
| Jan-19-18 | Initiated | Seaport Global Securities | Buy |
| Jan-04-18 | Reiterated | Canaccord Genuity | Buy |
| Jan-03-18 | Initiated | Leerink Partners | Mkt Perform |
View All
Pacira Biosciences Inc Stock (PCRX) Latest News
Deals tracker: IKS Health acquires TruBridge in $557M deal - Modern Healthcare
Pacira BioSciences stock trades steady as pain-management pipeline stays in focus - ad-hoc-news.de
Understanding the Setup: (PCRX) and Scalable Risk - Stock Traders Daily
82P Forecast — Price Target — Prediction for 2027 - TradingView
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - markets.businessinsider.com
Pacira uses stock awards to recruit 10 new employees - Stock Titan
Pacira BioSciences (PCRX) Wins Broader EXPAREL Reimbursement, Is The Stock Still Undervalued? - Sahm
Zimmer Biomet acquires rights to medical device for $140 million - Inside INdiana Business
Enterprise value to revenue forward of Pacira Biosciences, Inc. – BX:82P - TradingView
PCRX's Exparel Wins Separate Reimbursement From UnitedHealthcare - TradingView
Pacira to divest iovera business to Zimmer Biomet in up to $140M deal - MSN
UnitedHealthcare adds separate reimbursement for Exparel By Investing.com - Investing.com Australia
Sector Update: Healthcare - Moomoo
Pacira to Divest iovera Business to Zimmer Biomet in Up To $140M Deal - TradingView
Pacira BioSciences to divest its iovera° business to Zimmer Biomet - Medical Buyer
Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL - markets.businessinsider.com
Pacira BioSciences' Exparel Now Separately Reimbursed by UnitedHealthcare Across Outpatient Settings - marketscreener.com
PCRX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $38 - GuruFocus
Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL® - The Manila Times
Zimmer Biomet to acquire iovera device from Pacira for $140m - Yahoo Finance
H.C. Wainwright Maintains Pacira BioSciences(PCRX.US) With Buy Rating, Maintains Target Price $38 - Moomoo
Price to earnings forward of Pacira BioSciences, Inc. – NASDAQ:PCRX - TradingView
Pacira BioSciences (PCRX) Sells iovera° Business to Zimmer Biome - GuruFocus
Zimmer Biomet Holdings, Inc. agreed to acquire iovera ° Business of Pacira BioSciences from Pacira BioSciences, Inc. for $140 million. - marketscreener.com
Needham Maintains Pacira BioSciences(PCRX.US) With Buy Rating, Maintains Target Price $32 - Moomoo
Pacira Biosciences Announces Agreement to Div - Moomoo
Zimmer to buy Pacira pain relief device for up to $140M - MedTech Dive
Pacira divests iovera device to Zimmer Biomet for up to $140m - Investing.com
Pacira Biosciences Announces Agreement To Divest Its Iovera° Business To Zimmer Biomet - TradingView
Pacira BioSciences stock rises on Zimmer Biomet deal By Investing.com - Investing.com South Africa
Pacira BioSciences stock rises on Zimmer Biomet deal - Investing.com UK
Pacira BioSciences Divests CryoTech to Zimmer Biomet - TipRanks
Pacira BioSciences Announces Agreement to Divest its iovera° Business to Zimmer Biomet - The Manila Times
Pacira BioSciences Sells iovera° Device to Zimmer Biomet in $140 Million Deal, Focuses on Biopharma Innovation - Minichart
Pacira BioSciences to Divest iovera° to Zimmer Biomet for Up to $140 Million - Quiver Quantitative
Pacira BioSciences to Sell Iovera Cryoanalgesia Business to Zimmer for Up to $140 Million - TradingView
Pacira (NASDAQ: PCRX) divests iovera° business to Zimmer Biomet for up to $140M - Stock Titan
Pacira offloads iovera° for up to $140M, keeps spasticity program - Stock Titan
Pacira Biosciencesto Use Upfront Proceeds - Moomoo
PCRX Forecast — Price Target — Prediction for 2027 - TradingView
Pacira Biosciences, Inc. Actuals & Estimates (NASDAQ:PCRX) - TradingView
Price to book forward of Pacira BioSciences, Inc. – NASDAQ:PCRX - TradingView
Enterprise value to EBIT forward of Pacira BioSciences, Inc. – NASDAQ:PCRX - TradingView
Enterprise value to EBIT forward of Pacira Biosciences, Inc. – FWB:82P - TradingView
Price to sales forward of Pacira BioSciences, Inc. – NASDAQ:PCRX - TradingView
Enterprise value to revenue forward of Pacira Biosciences, Inc. – FWB:82P - TradingView
Pacira BioSciences, Inc.(NasdaqGS: PCRX) added to Russell 2000 Value-Defensive Index - marketscreener.com
Pacira BioSciences, Inc.(NasdaqGS: PCRX) added to Russell 2000 Growth-Defensive Index - marketscreener.com
Price to earnings forward of Pacira Biosciences, Inc. – FWB:82P - TradingView
Price to sales forward of Pacira Biosciences, Inc. – FWB:82P - TradingView
The Technical Signals Behind (PCRX) That Institutions Follow - Stock Traders Daily
Pacira Biosciences Inc Stock (PCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.42%
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):